Calypte Biomedical Receives Letter of Intent For $ 4 Million Purchase Order From World Vision Africa
ALAMEDA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today that it has received a letter from World Vision Africa, one of the largest NGOs (non-government organization) in Africa, outlining an intent to purchase $4 million of Calypte's urine based HIV/AIDS tests.
In a letter dated September 16, 2003, Mr. Dida Guyo, Procurement Officer for World Vision's Africa Regional Office in Nairobi, Kenya, stated that World Vision Africa spends over $1 million quarterly on HIV tests and that World Vision Africa commits to change this quarterly purchase of HIV tests from the standard blood tests to Calypte Biomedical's urine based HIV/AIDS test.
The purchase is contingent upon the imminent approval of Calypte's urine based tests by the Kenyan National Laboratory. Mr. Guyo stated that since the urine tests have been approved by the FDA, WHO and in neighboring Uganda, then he sees the Kenyan approval process a formality. Mr. Guyo also stated that there is strong support in Africa for non-invasive HIV/AIDS tests.
Jay Oyakawa, President of Calypte stated, "We are aggressively coordinating our efforts to receive final approval from the Republic of Kenya and believe that approval is imminent."
About World Vision:
World Vision is an international Christian relief and development organization working to promote the well being of all people -- especially children. In 2002, World Vision offered material, emotional, social and spiritual support to 85 million people in 96 countries.
|
Thread abonnieren
